logo

Seelos Therapeutics, Inc (SEEL)



Trade SEEL now with
  Date
  Headline
2/18/2021 7:04:54 AM Seelos Therapeutics Amends Deal With Vyera Pharma To Repurchase Significant Portion Of Royalties For SLS-002
1/29/2021 8:02:59 AM Seelos Therapeutics Announces Issuance Of A Patent For Trehalose In Australia
1/28/2021 10:18:12 AM Seelos Therapeutics Announces Closing Of Public Offering Of Common Stock
1/27/2021 8:04:16 AM Seelos Therapeutics Announces Inclusion In The First Psychedelic Exchange Traded Fund
1/26/2021 8:31:49 AM Seelos Therapeutics Reports Pricing Of $31.25 Mln Public Offering Of Common Stock
1/25/2021 4:05:06 PM Seelos Therapeutics Begins Public Offering Of Shares Of Common Stock
1/22/2021 9:01:15 AM Seelos Therapeutics Receives Notice Of Allowance In Japan For SLS-005
1/15/2021 8:31:38 AM Seelos Therapeutics Announces Dosing Of The First Patients In Registrational Proof Of Concept Study Of SLS-002
1/6/2021 8:47:45 AM Seelos Therapeutics Says Achieved Several Major Milestones In 2020
1/5/2021 9:01:45 AM Seelos Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule
12/21/2020 9:02:29 AM Seelos Therapeutics Announces Issuance Of Patent For Trehalose In Israel
12/15/2020 9:02:12 AM Seelos Says Phase IIb/III Study Of SLS-005 Selected To Be Included In HEALEY ALS Platform Trial
11/19/2020 8:51:10 AM Seelos Therapeutics Gets US Orphan Drug Designation For SLS-005 In Amyotrophic Lateral Sclerosis
9/23/2020 9:04:32 AM Seelos Announces Sponsored Research Deal With Duke University For Gene Therapy Studies Of SLS-004 In Parkinson's Disease
9/14/2020 9:05:43 AM Seelos Announces Issuance Of New Patent And Additional Notice Of Allowance In Japan For Intranasal Racemic Ketamine
9/10/2020 9:07:32 AM Seelos Therapeutics Receives Notice Of Allowance For An Additional US Patent For Trehalose
9/9/2020 2:30:09 PM Seelos Therapeutics Announces Closing Of $7 Mln Registered Direct Offering